Sana Corp (SANA) - Market Cap to Net Income Ratio

Corporate emblem and logo of Sana Biotechnology Inc (SANA)

High scientific risks at Sana Biotechnology (SANA) create volatility, as evidenced by the P/E ratio. The -4.10 mark reflects the latest market valuation data. Stability will be provided by the universal cell platform for treating diabetes and cancer, while growth potential is embedded in innovative in vivo drugs currently at the start of clinical trials.

SANA sana.com: Price to Earnings Ratio in the range 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Sana Bio (SANA)

- market price and analyst price targets:
Market Price sana.com|SANA - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Sana Biotechnology, Inc.|SANA - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Net Asset Value per Share Sana Biotechnology|SANA - Company Net Assets|Market Value to Book Value sana.com|SANA - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Sana Biotechnology|SANA - Long-Term Debt to Capital|Current Liabilities to Capital Sana Corp|SANA - Company Debts|Debt to Book Capitalization Ratio Sana Biotechnology, Inc.|SANA - Company Long-Term Debt|Company Short-Term Debt Sana Biotechnology|Intermediate Coverage Ratio sana.com
- business earnings and investment ratios data:
SANA - Net Profit|Projected Net Profit Sana Biotechnology|SANA - P/E Multiple|Projected Price to Earnings Ratio Sana Biotechnology Inc|SANA - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Sana Biotechnology, Inc.|SANA - Operating profit EBITDA|Net earnings per one share for the last twelve months Sana Biotechnology|SANA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months sana.com|SANA - Net earnings per share growth this year|Projected earnings per share increase next year Sana Biotechnology
- issuer revenue and sales details:
SANA - Revenue and Sales Volume|Company Future Revenue sana.com|SANA - P/S Multiple|Market Cap to Future Revenue Ratio Sana Biotechnology, Inc.
Comprehensive company analysis:sana.com
Signature product of Sana Biotechnology, Inc.

The P/E ratio reflects the market value of a single unit of profit, allowing investors to determine the extent of an asset's overvaluation or identify hidden fundamental risks. By analyzing the average P/E of the company, market participants assess the capitalization potential of Sana Biotechnology (SANA), whose ambitions in living tissue programming and in vivo organ regeneration render classic earnings valuations secondary to the value of future breakthrough innovations.

Analysis of competing companies

Market Cap to Earnings legendbiotech.com LEGN|P/E Multiple AUTL|Allogene Therapeutics, Inc. (ALLO) - Market Cap to Net Income Ratio|Cartesian Therapeutics Inc - Price to Earnings Ratio|Cellectis SA (CLLS) - Market Cap to Earnings|CRBU: Price to Earnings Ratio|Company Value to Net Income TIL (instilbio.com)|GNTA: P/E Multiple|Price to Earnings Ratio Century Therapeutics, Inc.|JSPR (Jasper Therapeutics Inc) - P/E Multiple|Market Cap to Earnings Senti Biosciences Inc SNTI|Price to Earnings Ratio Adaptimmune (ADAP)|Price to Earnings Ratio CERO (cero.bio)|Price to Earnings Ratio Alaunos Therapeutics, Inc. TCRT|Achilles Therapeutics PLC - Price to Earnings Ratio|CRGX: Price to Earnings Ratio|Company Value to Net Income PSTX (Poseida Corp)|TSVT: P/E Multiple|Market Cap to Net Income Ratio gracellbio.com GRCL